Generic Name
Brand Name FDA Approval Date
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide fumarate, EVG / COBI / FTC / TAF) Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (QUAD, EVG / COBI / FTC / TDF) Emtricitabine, rilpivirine, and tenofovir alafenamide (emtricitabine / rilpivirine / tenofovir AF, emtricitabine / rilpivirine / tenofovir alafenamide fumarate, emtricitabine / rilpivirine hydrochloride / tenofovir AF, emtricitabine / rilpivirine hydrochloride / tenofovir alafenamide, emtricitabine / rilpivirine hydrochloride / tenofovir alafenamide fumarate, FTC / RPV / TAF) Emtricitabine, rilpivirine, and tenofovir disoproxil fumarate (emtricitabine / rilpivirine hydrochloride / tenofovir disoproxil fumarate, emtricitabine / rilpivirine / tenofovir, FTC / RPV / TDF) Emtricitabine and tenofovir alafenamide (emtricitabine / tenofovir AF, emtricitabine / tenofovir alafenamide fumarate, FTC / TAF) Emtricitabine and tenofovir disoproxil fumarate (emtricitabine / tenofovir DF, FTC / TDF)
Genvoya
November 5, 2015
Stribild
August 27, 2012
Odefsey
March 1, 2016
Complera August 10, 2011
Descovy
April 4, 2016
Truvada
August 2, 2004
Lamivudine and tenofovir disoproxil fumarate (Temixys, 3TC / TDF)
Cimduo Combivir
February 28, 2018 September 27, 1997 September 15, 2000
Lamivudine and zidovudine (3TC / ZDV)
Lopinavir and ritonavir (ritonavir-boosted lopinavir, LPV/r, LPV / RTV)
Kaletra
It is important to note that close medical supervision is required to determine individual combinations of anti-viral medication regimens. It is also critical to assess the ongoing
effectiveness of the drugs and to monitor adverse effects of these medications.
CHAPTER 4: TB AND HEPATITIS TRANSMISSION, PREVENTION, AND TREATMENT
Chapter overview This chapter defines the three types of viral hepatitis, TB, and coinfection with HIV in terms of symptoms, prevention and treatment. Chapter objectives Describe tuberculosis (TB) and types of hepatitis virus (HV).
Identify how TB and hepatitis are prevented, transmitted, and treated.
COINFECTION WITH HIV AND HEPATITIS C VIRUS
According to the CDC (2019c), about 1 in 10 people living with HIV are coinfected with hepatitis B virus (HBV), and about 1 in 4 people are coinfected with hepatitis C virus (HCV). Hepatitis B and C are liver infections caused by a virus. HCV is one of the main causes of chronic liver disease in the United States and HCV infection progresses more rapidly to liver damage in HIV-infected persons. HCV infection may Likely candidates for HIV-HCV coinfection The hepatitis C virus (HCV) is transmitted primarily by large or repeated direct percutaneous (i.e., passage through the skin by puncture) exposures to contaminated blood. Therefore, coinfection with HIV and HCV is common (50% to 90%) among HIV-infected injection drug users
also impact the course and management of HIV infection. The latest U.S. Public Health Service/Infectious Diseases Society of America (USPHS/IDSA) guidelines recommend that all HIV-infected persons should be screened for HCV infection. Prevention of HCV infection for those not already infected and reducing chronic liver disease in those who are infected are important concerns for HIV-infected individuals and their health care providers.
(IDUs). Coinfection is also common among persons with hemophilia who received clotting factor concentrates before concentrates were effectively treated to inactivate both viruses (i.e., products made before 1987).
Effects of coinfection on disease progression of HCV and HIV Chronic HCV infection develops in 50% of infected persons and leads to chronic liver disease in approximately 20% of these chronically infected persons. HIV-HCV coinfection has been associated with higher titers of HCV, more rapid progression to HCV-related liver disease, and an increased risk for HCV-related cirrhosis (scarring) of the liver. Because of this, HCV infection has been viewed as an opportunistic infection in HIV-infected persons. It is not, however,
considered an AIDS-defining illness. HCV-related liver disease has become a major cause of hospital admissions and deaths among HIV-infected persons. HIV/HCV- coinfected patients suffer from more liver-related morbidity and mortality, nonhepatic organ dysfunction, and overall mortality than HCV-monoinfected, infection with HCV only patients (AASLD, 2019).
Page 17
Book Code: CFL0425
EliteLearning.com/Cosmetology
Powered by FlippingBook